Advertisement

Oncology / Hematology Latest

Abiraterone acetate improves survival in high-risk non-metastatic prostate cancer

Sep 22, 2022

1. Abiraterone acetate plus standard treatment significantly increased length of metastasis-free survival in men with non-metastatic prostate cancer compared to control. 2. Regarding adverse events, h...

Risk of prostate cancer for men fathering through assisted reproduction

Aug 07, 2020

Assisted human reproduction (AHR) is the procedure in which eggs, sperms, or both are handled outside the human body. This helps couples who aren't able to conceive naturally, but recent studies have ...

CASPIAN Trial Update: Phase 3 Results & Perspectives

Jun 23, 2020

Updated findings from the phase 3 CASPIAN trial presented at the 2020 American Society of Clinical Oncology Virtual Scientific Program showed maintained overall survival (OS) benefit of durvalumab tre...

Addition of Chemo to Durvalumab/Tremelimumab Does Not Improve OS

Jun 23, 2020

In the phase 3 CCTG BR.34 trial, no additional effect on overall survival (OS) was observed by adding platinum-based chemotherapy to dual checkpoint inhibition in first-line advanced or metastatic con...

Ipilimumab/nivolumab given concomitantly with two cycles of chemotherapy demonstrated prolonged overall survival

Jun 23, 2020

Ipilimumab/nivolumab given concomitantly with two cycles of chemotherapy demonstrated prolonged overall survival In the CheckMate 9LA trial, a statistically significant improvement in overall s...

ASCO: Breast Cancer Brain Mets Treated with Tucatinib

Jun 05, 2020

Addition of agent to chemotherapy improves survival The risk of death or progression of brain metastases was reduced if patients with breast cancer added tucatinib (Tukysa) to a regimen of trastuzuma...

ASCO: Larotrectinib Produces Durable Responses

Jun 04, 2020

TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers — from thyroid to breast cancer — appear to have durable responses when treated with larotrectini...

ASCO: Survival Benefit Emerges in ARAMIS

Jun 03, 2020

Darolutamide better in non-metastatic castration-resistant prostate cancer Men diagnosed with non-metastatic castration-resistant prostate cancer live longer if they are treated with darolutamide (Nu...

ASCO: Consultant Palliation Improves AML Quality of Life

Jun 03, 2020

Early referral linked to better psychological outcomes Referring a patient diagnosed with acute myeloid leukemia (AML) to the palliation service at the time grueling therapy begins appears to offer p...

ASCO: Gastric Cancer Patients Respond to Trastuzumab Deruxtecan

Jun 02, 2020

Overall survival also extended with conjugate treatment In a small, phase II trial, patients with advanced gastric cancer were far more likely to respond to conjugate therapy with trastuzumab deruxte...

ASCO: Oral GnRH Antagonist Superior to Leuprolide Injection in Prostate Cancer

Jun 02, 2020

HERO findings also confirm fewer cardiovascular events with relugolix More than 96% of men with advanced prostate cancer who were treated with relugolix, an oral, highly selective gonadatropin-releas...

ASCO 2020: Relugolix Superior to Leuprolide in Advanced Prostate Cancer

May 30, 2020

FRIDAY, May 29, 2020 (HealthDay News) -- For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the...